Shanghai Pharmaceuticals Holding Co (HK:2607) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Shanghai Pharmaceuticals Holding Co. has renewed its Sales and Procurement Framework Agreement with Yunnan Baiyao for 2025, securing another year of collaboration. The partnership involves the exchange of medicines, medical devices, and health products, leveraging each company’s strength as a producer or main distributor. This agreement, a continuing connected transaction, will not require independent shareholders’ approval under Hong Kong’s listing rules.
For further insights into HK:2607 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Arrived Helps Investors Cash In on the Single-Family Rental Boom
- Top Investor Raises Red Flags on Super Micro Computer Stock
- ‘Stay Away for Now,’ Says Top Investor About Nvidia Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
